A5007253703- SARS-CoV-2 and COVID-19 Research
- Transgenic Plants and Applications
- COVID-19 Clinical Research Studies
- Toxin Mechanisms and Immunotoxins
- Viral gastroenteritis research and epidemiology
- Viral Infections and Vectors
- Fire effects on ecosystems
- Heparin-Induced Thrombocytopenia and Thrombosis
- Microbial Inactivation Methods
- COVID-19 diagnosis using AI
- Bacterial Infections and Vaccines
- Vector-Borne Animal Diseases
- Viral Infections and Outbreaks Research
- Animal Virus Infections Studies
- vaccines and immunoinformatics approaches
- SARS-CoV-2 detection and testing
- Influenza Virus Research Studies
- Extracellular vesicles in disease
- Mosquito-borne diseases and control
Erciyes University
2020-2025
Research & Development Institute
2025
The rapid spread of SARS-CoV-2 with its mutating strains has posed a global threat to safety during this COVID-19 pandemic. Thus far, there are 123 candidate vaccines in human clinical trials and more than 190 candidates preclinical development worldwide as per the WHO on 1 October 2021. various types that currently approved for emergency use include viral vectors (e.g., adenovirus, University Oxford/AstraZeneca, Gamaleya Sputnik V, Johnson & Johnson), mRNA (Moderna Pfizer-BioNTech), whole...
Background/Objectives: The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the emergence variants with enhanced transmissibility and immune evasion, challenging existing vaccines. This study aimed evaluate immunogenicity protective efficacy inactivated bivalent vaccine formulations incorporating ancestral SARS-CoV-2 strain (ERAGEM) either Delta or Omicron (BA.5) variants. Methods: Bivalent were prepared using beta-propiolactone-inactivated antigens...
The COVID-19 pandemic has put global public health at high risk, rapidly spreading around the world. Although several vaccines are available for mass immunization, world still urgently needs highly effective, reliable, cost-effective, and safe SARS-CoV-2 coronavirus vaccines, as well antiviral therapeutic drugs, to control given emerging variant strains of virus. Recently, we successfully produced receptor-binding domain (RBD) variants in Nicotiana benthamiana plant promising vaccine...
The COVID-19 pandemic, caused by SARS-CoV-2, has rapidly spread to more than 222 countries and put global public health at high risk. world urgently needs cost-effective safe SARS-CoV-2 vaccines, antiviral, therapeutic drugs control it. In this study, we engineered the receptor binding domain (RBD) of spike (S) protein produced it in plant Nicotiana benthamiana a glycosylated deglycosylated form. Expression levels both (gRBD) (dRBD) RBD were greater 45 mg/kg fresh weight. purification yields...
Development of safe and effective vaccine options is crucial to the success fight against COVID-19 pandemic. Herein, we report interim safety immunogenicity findings phase 1&2 trials ERUCoV-VAC, an inactivated whole virion SARS-CoV-2 vaccine.Double-blind, randomised, single centre, 1 2 included seronegative healthy adults aged 18-55 years (18-64 in 2). All participants, except first 4 who received ERUCoV-VAC 3 μg or 6 unblinded monitored for 7 days purposes, were assigned receive two...
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and associated with illness emerged in Wuhan, China, late 2019. The virus has been able to spread promptly across all continents the world. current pandemic posed a great threat public health concern safety. Currently, there are no specific treatments or licensed vaccines available for COVID-19. We isolated SARS-CoV-2 from nasopharyngeal sample of patient Turkey confirmed determined...
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne in the Nairoviridae family within Bunyavirales order of viruses. (CCHF) most widespread among human viral diseases. It endemic many areas Africa, Asia, Middle East, Balkans, Russia and countries former Soviet Union. The confirmed CCHF cases were seen Spain 2016 to signify expansion into new geographical areas. CCHFV causes disease characterized by sudden onset fever, headache, abdominal pain, nausea, hypotension, hemorrhage,...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel and highly pathogenic that caused an outbreak in Wuhan City, China, 2019 then spread rapidly throughout the world. Although several disease (COVID-19) vaccines are currently available for mass immunization, they less effective against emerging SARS-CoV-2 variants, especially Omicron (B.1.1.529). Recently, we successfully produced receptor-binding domain (RBD) variants of spike (S) protein antigen cocktail Nicotiana...
The scale of the COVID-19 pandemic forced urgent measures for development new therapeutics. One these strategies is use convalescent plasma (CP) as a conventional source passive immunity. Recently, there has been interest in CP-derived exosomes. In this report, we present structural, biochemical, and biological characterization our proprietary product, human immune plasma-derived exosome (ChipEXO), following guidelines set forth by Turkish Ministry Health Red Crescent, Good Manufacturing...
Vaccine-induced immunity wanes over time and warrants booster doses. We investigated the long-term (32 weeks) immunogenicity safety of a third, homologous, open-label dose TURKOVAC, administered 12 weeks after completion primary series in randomized, controlled, double-blind, phase 2 study. Forty-two participants included analysis were evaluated for neutralizing antibodies (NAbs) (with microneutralization (MNT50) focus reduction (FRNT50) tests), SARS-CoV-2 S1 RBD (Spike Receptor Binding...
SARS-CoV-2, the virus responsible for COVID-19 pandemic, belongs to betacoronavirus genus. This has a high mutation rate, which rapidly evolves into new variants with different properties, such as increased transmissibility or immune evasion. Currently, most prevalent global SARS-CoV-2 variant is Omicron, more transmissible than previous variants. Current available vaccines may be less effective against some currently existing variants, including Omicron variant. The S1 subunit of spike...
Abstract SARS-CoV-2 is a novel and highly pathogenic coronavirus, which has caused an outbreak in Wuhan City, China, 2019 then spread rapidly throughout the world. Although several COVID-19 vaccines are currently available for mass immunization, they less effective against emerging variants, especially Omicron (B.1.1.529). Recently, we successfully produced receptor-binding domain (RBD) variants of spike (S) protein SARC-CoV-2 antigen cocktail Nicotiana benthamiana , plants elicited...
Background: Safe and effective vaccine options is crucial to fight against COVID-19 pandemic. We report interim safety immunogenicity findings of the phase 1&2 trials ERUCoV-VAC, an inactivated whole virion SARS-CoV-2 vaccine. Methods: Double-blind, randomised, single centre, included seronegative healthy adults aged 18-55 years (18-64 in 2). Participants, were assigned receive two intramuscular doses ERUCoV-VAC 3µg or 6µg placebo 21 days apart (28 2) via computer-generated randomisation....